Literature DB >> 22644792

Gender differences in adiponectin modulation of cardiac remodeling in mice deficient in endothelial nitric oxide synthase.

Jorge L Durand1, Andrea R Nawrocki, Philipp E Scherer, Linda A Jelicks.   

Abstract

Left ventricular hypertrophy (LVH) is a risk factor for cardiovascular disease, a leading cause of death. Alterations in endothelial nitric oxide synthase (eNOS), an enzyme involved in regulating vascular tone, and in adiponectin, an adipocyte-derived secretory factor, are associated with cardiac remodeling. Deficiency of eNOS is associated with hypertension and LVH. Adiponectin exhibits vaso-protective, anti-inflammatory, and anti-atherogenic properties. We hypothesized that increased levels of adiponectin would alleviate cardiac pathology resulting from eNOS deficiency, while decreased levels of adiponectin would exacerbate the pathology. Male and female mice, deficient in eNOS, and either lacking or over-expressing adiponectin, were fed high fat diet (HFD) or normal chow. Cardiac magnetic resonance imaging was performed to serially assess heart morphology and function up to 40 weeks of age. Thirty-two weeks of HFD feeding led to significantly greater LV mass in male mice deficient in eNOS and either lacking or over-expressing adiponectin. Heart function was significantly reduced when the mice were deficient in either eNOS, adiponectin or both eNOS and adiponectin; for female mice, heart function was only reduced when both eNOS and adiponectin were lacking. Thus, while over-expression of adiponectin in the eNOS deficient HFD fed male mice preserved function at the expense of significantly increased LV mass, female mice were protected from decreased function and increased LVH by over-expression of adiponectin. Our results demonstrate a sexual dimorphism in response of the heart to alterations in eNOS and adiponectin during high fat feeding and suggest that adiponectin might require eNOS for some of its metabolic effects.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22644792      PMCID: PMC4268866          DOI: 10.1002/jcb.24206

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  48 in total

1.  Left ventricular mass change during treatment and outcome in patients with essential hypertension.

Authors:  Michael J Koren; Roy J Ulin; Andrew T Koren; John H Laragh; Richard B Devereux
Journal:  Am J Hypertens       Date:  2002-12       Impact factor: 2.689

2.  Regression of left ventricular hypertrophy and prevention of stroke in hypertensive subjects.

Authors:  Paolo Verdecchia; Fabio Angeli; Roberto Gattobigio; Mariagrazia Sardone; Sergio Pede; Gian Paolo Reboldi
Journal:  Am J Hypertens       Date:  2006-05       Impact factor: 2.689

3.  Circulating adiponectin concentrations in patients with congestive heart failure.

Authors:  J George; S Patal; D Wexler; Y Sharabi; E Peleg; Y Kamari; E Grossman; D Sheps; G Keren; A Roth
Journal:  Heart       Date:  2006-04-18       Impact factor: 5.994

4.  Neuronal NOS-dependent dilation to flow in coronary arteries of male eNOS-KO mice.

Authors:  An Huang; Dong Sun; Edward G Shesely; Ellen M Levee; Akos Koller; Gabor Kaley
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-02       Impact factor: 4.733

5.  Globular and full-length adiponectin induce NO-dependent vasodilation in resistance arteries of Zucker lean but not Zucker diabetic fatty rats.

Authors:  Peter M Schmid; Markus Resch; Andreas Steege; Sabine Fredersdorf-Hahn; Benjamin Stoelcker; Christoph Birner; Christian Schach; Christa Buechler; Guenter A J Riegger; Andreas Luchner; Dierk H Endemann
Journal:  Am J Hypertens       Date:  2010-12-09       Impact factor: 2.689

Review 6.  Cardiac fibrosis as a cause of diastolic dysfunction.

Authors:  Brad S Burlew; Karl T Weber
Journal:  Herz       Date:  2002-03       Impact factor: 1.443

Review 7.  Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction.

Authors:  Thomas Münzel; Christoph Sinning; Felix Post; Ascan Warnholtz; Eberhard Schulz
Journal:  Ann Med       Date:  2008       Impact factor: 4.709

8.  Adiponectin and risk of coronary heart disease in older men and women.

Authors:  Jorge R Kizer; Joshua I Barzilay; Lewis H Kuller; John S Gottdiener
Journal:  J Clin Endocrinol Metab       Date:  2008-07-01       Impact factor: 5.958

9.  Pressure overload-induced LV hypertrophy and dysfunction in mice are exacerbated by congenital NOS3 deficiency.

Authors:  Fumito Ichinose; Kenneth D Bloch; Justina C Wu; Ryuji Hataishi; H Thomas Aretz; Michael H Picard; Marielle Scherrer-Crosbie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-11-26       Impact factor: 4.733

10.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis.

Authors:  Ebba Bråkenhielm; Niina Veitonmäki; Renhai Cao; Shinji Kihara; Yuji Matsuzawa; Boris Zhivotovsky; Tohru Funahashi; Yihai Cao
Journal:  Proc Natl Acad Sci U S A       Date:  2004-02-24       Impact factor: 11.205

View more
  9 in total

1.  Estrogen-Dependent Disruption of Adiponectin-Connexin43 Signaling Underlies Exacerbated Myocardial Dysfunction in Diabetic Female Rats.

Authors:  Korin E Leffler; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2018-12-06       Impact factor: 4.030

Review 2.  Sex differences in obesity-induced hypertension and vascular dysfunction: a protective role for estrogen in adipose tissue inflammation?

Authors:  Lia E Taylor; Jennifer C Sullivan
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-08-10       Impact factor: 3.619

3.  Decreased levels of proapoptotic factors and increased key regulators of mitochondrial biogenesis constitute new potential beneficial features of long-lived growth hormone receptor gene-disrupted mice.

Authors:  Adam Gesing; Michal M Masternak; Andrzej Lewinski; Malgorzata Karbownik-Lewinska; John J Kopchick; Andrzej Bartke
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-11-29       Impact factor: 6.053

4.  Involvement of adiponectin in early stage of colorectal carcinogenesis.

Authors:  Chung Hyun Tae; Seong-Eun Kim; Sung-Ae Jung; Yang-Hee Joo; Ki-Nam Shim; Hye-Kyung Jung; Tae Hun Kim; Min-Sun Cho; Kwang Ho Kim; Joung Sook Kim
Journal:  BMC Cancer       Date:  2014-11-05       Impact factor: 4.430

Review 5.  Role of Adiponectin in Central Nervous System Disorders.

Authors:  Jenna Bloemer; Priyanka D Pinky; Manoj Govindarajulu; Hao Hong; Robert Judd; Rajesh H Amin; Timothy Moore; Muralikrishnan Dhanasekaran; Miranda N Reed; Vishnu Suppiramaniam
Journal:  Neural Plast       Date:  2018-07-29       Impact factor: 3.599

6.  Premature Myocardial Infarction: Genetic Variations in SIRT1 Affect Disease Susceptibility.

Authors:  Aylin Hatice Yamac; Omer Uysal; Ziya Ismailoglu; Mehmet Ertürk; Mert Celikten; Ahmet Bacaksiz; Ulkan Kilic
Journal:  Cardiol Res Pract       Date:  2019-04-15       Impact factor: 1.866

7.  SIRT1 gene polymorphisms affect the protein expression in cardiovascular diseases.

Authors:  Ulkan Kilic; Ozlem Gok; Ahmet Bacaksiz; Muzeyyen Izmirli; Birsen Elibol-Can; Omer Uysal
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

8.  Circulating adiponectin and cardiovascular mortality in patients with type 2 diabetes mellitus: evidence of sexual dimorphism.

Authors:  Claudia Menzaghi; Min Xu; Lucia Salvemini; Concetta De Bonis; Giuseppe Palladino; Tao Huang; Massimiliano Copetti; Yan Zheng; Yanping Li; Grazia Fini; Frank B Hu; Simonetta Bacci; Lu Qi; Vincenzo Trischitta
Journal:  Cardiovasc Diabetol       Date:  2014-09-10       Impact factor: 9.951

9.  Deficiency of eNOS exacerbates early-stage NAFLD pathogenesis by changing the fat distribution.

Authors:  Yuichi Nozaki; Koji Fujita; Koichiro Wada; Masato Yoneda; Yoshiyasu Shinohara; Kento Imajo; Yuji Ogawa; Takaomi Kessoku; Makoto Nakamuta; Satoru Saito; Naohiko Masaki; Yoji Nagashima; Yasuo Terauchi; Atsushi Nakajima
Journal:  BMC Gastroenterol       Date:  2015-12-17       Impact factor: 3.067

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.